Currently available therapies such as niacin and PCSK9 inhibitors such as Repatha (evolocumab) and Praluent (alirocumab) can reduce Lp (a) levels, but their impact is modest. Another challenge in ...
News-Medical.Net on MSN
Aptamer Group and Alphazyme execute licensing agreement for synthetic aptamer-based enzyme modulation in hot-start PCR
Aptamer Group plc, a developer of synthetic oligonucleotide-based binding reagents for life sciences applications, and Alphazyme LLC (Alphazyme), a Maravai LifeSciences company specializing in enzymes ...
Pancreatic cancer is notoriously hard to treat, often resisting therapies that target its most common mutations. Researchers ...
Peptide therapeutics have progressed from insulin discovery to GLP-1 class molecules, revolutionizing diabetes treatment and ...
RYTELO® (imetelstat) net product revenue expected in the range of $220 to $240 million2026 total operating expenses expected in the range of ...
Pancreatic ductal adenocarcinoma (PDAC) is both the most common and the deadliest type of pancreatic cancer. Most treatment ...
Zacks.com on MSN
Three Genomics Stocks Worth Tracking This Year
An updated edition of the Nov. 18, 2025, article. Genomics is a broad and detailed study of genomes (an organism’s complete ...
Gene-editing technologies show great promise for medical treatments and research, with the potential to cure thousands of ...
Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback